D-erythro-Pentonamide, 2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-, sulfate (1:1)
| Title | Journal |
|---|---|
| Effect of HIV protease inhibitors on New World Leishmania. | Parasitology international 20121201 |
| Role of FAP48 in HIV-associated lipodystrophy. | Journal of cellular biochemistry 20121101 |
| Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study. | AIDS research and human retroviruses 20121001 |
| Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil. | AIDS research and human retroviruses 20120901 |
| Simultaneous quantitation of HIV-protease inhibitors ritonavir, lopinavir and indinavir in human plasma by UPLC-ESI-MS-MS. | Journal of chromatographic science 20120801 |
| Regression analysis based on conditional likelihood approach under semi-competing risks data. | Lifetime data analysis 20120701 |
| Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans. | Canadian journal of microbiology 20120701 |
| Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. | European journal of clinical pharmacology 20120501 |
| Indinavir inhibits the expression of cytoplasmic aromatase and nuclear SREBP in the hippocampus of reperfusion injury-induced ischemic rats. | The Journal of steroid biochemistry and molecular biology 20120501 |
| Validating the vitality strategy for fighting drug resistance. | Proteins 20120401 |
| Comparison of extraction procedures for assessment of matrix effect for selective and reliable determination of atazanavir in human plasma by LC-ESI-MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120215 |
| Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). | Anesthesiology 20120201 |
| Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. | AIDS (London, England) 20120128 |
| The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes. | Journal of neurochemistry 20120101 |
| Suppression of pre adipocyte differentiation and promotion of adipocyte death by anti-HIV drugs. | In vivo (Athens, Greece) 20120101 |
| Impact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein. | PloS one 20120101 |
| Impact of short-term HAART initiated during the chronic stage or shortly post-exposure on SIV infection of male genital organs. | PloS one 20120101 |
| Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. | PloS one 20120101 |
| Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo. | Parasitology research 20111201 |
| HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. | The Lancet. Infectious diseases 20111001 |
| Chronic use of indinavir in albino rat pregnancy (Rattus norvegicus albinus, Rodentia, Mammalia): biological assay. | The journal of obstetrics and gynaecology research 20110901 |
| Brain delivery of transferrin coupled indinavir submicron lipid emulsions--pharmacokinetics and tissue distribution. | Colloids and surfaces. B, Biointerfaces 20110901 |
| The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against Cryptosporidium parvum. | Parasitology 20110901 |
| Pairwise additivity of energy components in protein-ligand binding: the HIV II protease-Indinavir case. | The Journal of chemical physics 20110828 |
| Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells. | British journal of cancer 20110809 |
| UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110801 |
| Indinavir-induced nephrolithiasis three and one-half years after cessation of indinavir therapy. | International urology and nephrology 20110601 |
| Fluorescence spectroscopy as tool for bone development monitoring in newborn rats. | Journal of fluorescence 20110501 |
| Surface structured liposomes for site specific delivery of an antiviral agent-indinavir. | Journal of drug targeting 20110501 |
| Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. | Free radical biology & medicine 20110401 |
| Brain specific delivery of pegylated indinavir submicron lipid emulsions. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110318 |
| Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. | Journal of controlled release : official journal of the Controlled Release Society 20110310 |
| Development of indinavir submicron lipid emulsions loaded with lipoamino acids-in vivo pharmacokinetics and brain-specific delivery. | AAPS PharmSciTech 20110301 |
| Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir. | Therapeutic drug monitoring 20110201 |
| Indinavir resistance evolution: a comment. | Virologica Sinica 20110201 |
| Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases. | International journal of cancer 20110101 |
| Identification of clinically used drugs that activate pregnane X receptors. | Drug metabolism and disposition: the biological fate of chemicals 20110101 |
| The anti-tumor effects of human immunodeficiency virus protease inhibitors: ready for real time? | International journal of cancer 20110101 |
| Renal disease associated with antiretroviral therapy in the treatment of HIV. | Nephron. Clinical practice 20110101 |
| [Evidence-based therapeutic drug monitoring for indinavir]. | Therapie 20110101 |
| Pre-steady-state kinetics of interaction of wild-type and multiple drug-resistant HIV protease with first and second generation inhibitory drugs. | Doklady. Biochemistry and biophysics 20110101 |
| Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. | International journal of nanomedicine 20110101 |
| A predictive ligand-based Bayesian model for human drug-induced liver injury. | Drug metabolism and disposition: the biological fate of chemicals 20101201 |
| NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance. | Endocrinology 20101201 |
| CH05-10, a novel indinavir analog, is a broad-spectrum antitumor agent that induces cell cycle arrest, apoptosis, endoplasmic reticulum stress and autophagy. | Cancer science 20101201 |
| Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells. | Analytical and bioanalytical chemistry 20101201 |
| HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces. | Mycoses 20101101 |
| Skew-normal Bayesian nonlinear mixed-effects models with application to AIDS studies. | Statistics in medicine 20101015 |
| Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia. | Toxicological sciences : an official journal of the Society of Toxicology 20101001 |
| Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension. | American journal of physiology. Regulatory, integrative and comparative physiology 20101001 |
| Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification. | Virologica Sinica 20101001 |
| Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. | AIDS (London, England) 20100910 |
| Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes. | Nanomedicine : nanotechnology, biology, and medicine 20100801 |
| Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. | AIDS (London, England) 20100717 |
| Dynamic calibration of pharmacokinetic parameters in dose-finding studies. | Biostatistics (Oxford, England) 20100701 |
| Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes. | Journal of pharmaceutical sciences 20100601 |
| Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. | HIV medicine 20100501 |
| Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction. | Drug metabolism and disposition: the biological fate of chemicals 20100501 |
| Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. | Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20100401 |
| Pharmacokinetic properties of indinavir in rat: some limitations of noncompartmental analysis. | Drug development and industrial pharmacy 20100301 |
| Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. | Biopharmaceutics & drug disposition 20100301 |
| Specification of covariance structure in longitudinal data analysis for randomized clinical trials. | Statistics in medicine 20100220 |
| Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. | Drug metabolism and disposition: the biological fate of chemicals 20100101 |
| Optical and X-ray fluorescence spectroscopy studies of bone and teeth in newborn rats after maternal treatment with indinavir. | Photochemistry and photobiology 20100101 |
| Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS. | Journal of molecular graphics & modelling 20100101 |
| Antiretroviral medications: adverse effects on the kidney. | Advances in chronic kidney disease 20100101 |
| HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro. | The American journal of tropical medicine and hygiene 20100101 |
| Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers. | Intervirology 20100101 |
| [The maturation steps of human immunodeficiency virus and the role of proteolysis]. | Voprosy virusologii 20100101 |
| Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. | BMC gastroenterology 20100101 |
| Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. | Retrovirology 20100101 |
| In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. | Antiviral therapy 20100101 |
| A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. | HIV clinical trials 20100101 |
| Validation of a sensitive ion chromatography method for determination of monoethylsulfate in Indinavir sulfate drug substance. | Journal of pharmaceutical and biomedical analysis 20091205 |
| Impact of stimulatory pathways on adipogenesis and HIV-therapy associated lipoatrophy. | Experimental biology and medicine (Maywood, N.J.) 20091201 |
| NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. | Nanomedicine (London, England) 20091201 |
| Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. | The Journal of antimicrobial chemotherapy 20091101 |
| The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men. | Journal of acquired immune deficiency syndromes (1999) 20091001 |
| Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. | American journal of physiology. Regulatory, integrative and comparative physiology 20090901 |
| Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts. | Life sciences 20090812 |
| Spectrum of chronic kidney disease in HIV-infected patients. | HIV medicine 20090701 |
| Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. | European journal of clinical pharmacology 20090701 |
| Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. | Journal of immunology (Baltimore, Md. : 1950) 20090701 |
| HIV-1 antiretrovirals induce oxidant injury and increase intima-media thickness in an atherogenic mouse model. | Toxicology letters 20090622 |
| Rapid screening and characterization of drug metabolites using multiple ion monitoring dependent product ion scan and postacquisition data mining on a hybrid triple quadrupole-linear ion trap mass spectrometer. | Rapid communications in mass spectrometry : RCM 20090601 |
| Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. | Proteins 20090515 |
| Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice. | Journal of pharmaceutical sciences 20090501 |
| Characterization of human corneal epithelial cell model as a surrogate for corneal permeability assessment: metabolism and transport. | Drug metabolism and disposition: the biological fate of chemicals 20090501 |
| Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy--an extended haplotype of genetic variants increases risk in indinavir treatment. | Journal of hepatology 20090501 |
| Artificial neural networks in analysis of indinavir and its degradation products retention. | Talanta 20090415 |
| Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous pediatric anti-HIV/AIDS liquid formulations with improved patient compliance. | AAPS PharmSciTech 20090301 |
| Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. | The Journal of antimicrobial chemotherapy 20090301 |
| Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. | Anesthesiology 20090301 |
| Novel therapeutic biosensor for indinavir-a protease inhibitor antiretroviral drug. | Journal of pharmaceutical and biomedical analysis 20090220 |
| Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. | AIDS (London, England) 20090220 |
| Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. | AIDS (London, England) 20090220 |
| Murine cardiac mtDNA: effects of transgenic manipulation of nucleoside phosphorylation. | Laboratory investigation; a journal of technical methods and pathology 20090201 |
| [Atazanavir-induced nephrolithiasis]. | Enfermedades infecciosas y microbiologia clinica 20090201 |
| HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. | AIDS (London, England) 20090128 |
| Pestalofones A-E, bioactive cyclohexanone derivatives from the plant endophytic fungus Pestalotiopsis fici. | Bioorganic & medicinal chemistry 20090115 |
| Relationship between P-glycoprotein activity measured in peripheral blood mononuclear cells and indinavir bioavailability in healthy volunteers. | Journal of pharmaceutical sciences 20090101 |
| Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. | Clinical chemistry 20090101 |
| Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children. | Pharmacology 20090101 |
| Anti-HIV drugs for cancer therapeutics: back to the future? | The Lancet. Oncology 20090101 |
| P-gp inhibition potential in cell-based models: which 'calculation' method is the most accurate? | The AAPS journal 20081201 |
| Using AutoDock for ligand-receptor docking. | Current protocols in bioinformatics 20081201 |
| Pestalazines and pestalamides, bioactive metabolites from the plant pathogenic fungus Pestalotiopsis theae. | Journal of natural products 20081101 |
| Design and synthesis of sulfoximine based inhibitors for HIV-1 protease. | Bioorganic & medicinal chemistry letters 20081015 |
| Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. | Biochemical and biophysical research communications 20080912 |
| The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. | AIDS (London, England) 20080912 |
| Kinetics and mechanism of the hydrolytic degradation of indinavir: intramolecular catalysis. | Journal of pharmaceutical sciences 20080901 |
| Automated molecular simulation based binding affinity calculator for ligand-bound HIV-1 proteases. | Journal of chemical information and modeling 20080901 |
| Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors. | European journal of medicinal chemistry 20080701 |
| Quantitative analysis of antiretroviral drugs in lysates of peripheral blood mononuclear cells using MALDI-triple quadrupole mass spectrometry. | Analytical chemistry 20080701 |
| Profiling resistance-related mutations in the protease region of the pol gene: single genome sequencing of HIV in plasma and peripheral blood mononuclear cells. | AIDS research and human retroviruses 20080701 |
| Improved synthesis and pharmacological evaluation of racemic 11 -demethylcalanolide A. | Yao xue xue bao = Acta pharmaceutica Sinica 20080701 |
| Evaluation of thermal stability of indinavir sulphate using diffuse reflectance infrared spectroscopy. | Journal of pharmaceutical and biomedical analysis 20080609 |
| Quality control of protease inhibitors. | Journal of pharmaceutical sciences 20080601 |
| [Bilateral papillary necrosis during indinavir treatment]. | Presse medicale (Paris, France : 1983) 20080601 |
| Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia. | Pharmacology, biochemistry, and behavior 20080601 |
| Pestaloficiols A-E, bioactive cyclopropane derivatives from the plant endophytic fungus Pestalotiopsis fici. | Bioorganic & medicinal chemistry 20080601 |
| Renal manifestations in HIV-infected Jamaican children. | The West Indian medical journal 20080601 |
| Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. | British journal of clinical pharmacology 20080501 |
| Indinavir influences biological function of dendritic cells and stimulates antifungal immunity. | Journal of leukocyte biology 20080501 |
| [Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)]. | Medecine et maladies infectieuses 20080501 |
| Chloropupukeananin, the first chlorinated pupukeanane derivative, and its precursors from Pestalotiopsis fici. | Organic letters 20080403 |
| Association of antiretroviral therapy with fibrinogen levels in HIV-infection. | AIDS (London, England) 20080330 |
| HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. | American journal of physiology. Endocrinology and metabolism 20080301 |
| Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. | Cardiovascular toxicology 20080301 |
| Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301 |
| pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. | Journal of pharmaceutical sciences 20080201 |
| An integrated method for metabolite detection and identification using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection. | Journal of mass spectrometry : JMS 20080201 |
| HIV therapy, metabolic syndrome, and cardiovascular risk. | Current atherosclerosis reports 20080201 |
| Indinavir-associated toxicity mimicking urinary tuberculosis in a patient with AIDS. | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20080201 |
| The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. | Biochemistry 20080115 |
| Acquired reactive perforating collagenosis induced by indinavir in 2 patients with HIV disease. | European journal of dermatology : EJD 20080101 |
| Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. | Pharmacotherapy 20080101 |
| Two immunomodulators, curcumin and sulfasalazine, enhance IDV antiretroviral activity in HIV-1 persistently infected cells. | Archives of virology 20080101 |
| Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. | HIV clinical trials 20080101 |
| Application of rat in situ single-pass intestinal perfusion in the evaluation of presystemic extraction of indinavir under different perfusion rates. | Journal of the Formosan Medical Association = Taiwan yi zhi 20080101 |
| Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement. | Journal of neurovirology 20080101 |
| Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir. | BMC neuroscience 20080101 |
| [Urinary lithiasis secondary to medication in HIV+ patients receiving Indinavir]. | Archivos espanoles de urologia 20080101 |
| Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy. | Acta poloniae pharmaceutica 20080101 |
| Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. | BMC complementary and alternative medicine 20080101 |
| A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method. | Drug metabolism and pharmacokinetics 20080101 |
| Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters. | Journal of biopharmaceutical statistics 20080101 |
| [Indinavir-associated tubulointerstitial renal disease]. | Nephrologie & therapeutique 20071201 |
| The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model. | Statistics in medicine 20071130 |
| Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. | European journal of clinical pharmacology 20071101 |
| Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. | Basic & clinical pharmacology & toxicology 20071101 |
| Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. | AIDS (London, England) 20071018 |
| Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. | Cell death and differentiation 20071001 |
| HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. | Toxicology and applied pharmacology 20071001 |
| Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity. | European journal of clinical pharmacology 20071001 |
| Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus. | Bioorganic & medicinal chemistry letters 20071001 |
| Prevalence and factors associated with dry skin in HIV infection: the FRAM study. | AIDS (London, England) 20071001 |
| Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070915 |
| Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. | British journal of clinical pharmacology 20070901 |
| [Three patients with indinavir-related urolithiasis]. | Nederlands tijdschrift voor geneeskunde 20070818 |
| Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study. | Journal of acquired immune deficiency syndromes (1999) 20070801 |
| Central nervous system distribution kinetics of indinavir in rats. | The Journal of pharmacy and pharmacology 20070801 |
| Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring. | European journal of medical research 20070726 |
| [Rapid development of anemia in a HIV-positive patient with alpha-thalassemia after zidovudine therapy]. | Mikrobiyoloji bulteni 20070701 |
| Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. | Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20070601 |
| Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings. | Expert opinion on drug metabolism & toxicology 20070601 |
| Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment. | Infection 20070601 |
| Chronic renal failure among HIV-1-infected patients. | AIDS (London, England) 20070531 |
| A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. | Neurology 20070529 |
| Nephrotoxicity of antiretroviral therapy in an HIV-infected patient. | Kidney international 20070501 |
| Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. | Journal of acquired immune deficiency syndromes (1999) 20070501 |
| Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? | Expert opinion on pharmacotherapy 20070501 |
| Effects of antiretroviral therapy on tube-like network formation of human endothelial cells. | Biological & pharmaceutical bulletin 20070501 |
| Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20070401 |
| An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401 |
| Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults. | Therapeutic drug monitoring 20070401 |
| High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. | Journal of pharmaceutical and biomedical analysis 20070312 |
| Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma. | British journal of clinical pharmacology 20070301 |
| [Indinavir stones]. | Actas urologicas espanolas 20070301 |
| Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. | Virology 20070205 |
| Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. | Journal of pharmacokinetics and pharmacodynamics 20070201 |
| Less sensitive HIV-1 enzyme immunoassay as an adjuvant method for monitoring patients receiving antiretroviral therapy. | AIDS patient care and STDs 20070201 |
| HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. | AIDS research and human retroviruses 20070201 |
| Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination. | AIDS (London, England) 20070102 |
| Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101 |
| Influence of body temperature on indinavir crystallization under loop of Henle conditions. | The Journal of antimicrobial chemotherapy 20070101 |
| Urological management of indinavir-associated acute renal failure in HIV-positive patients. | International urology and nephrology 20070101 |
| Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. | The Pediatric infectious disease journal 20070101 |
| Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. | AIDS research and human retroviruses 20070101 |
| Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire. | AIDS research and human retroviruses 20070101 |
| MSE with mass defect filtering for in vitro and in vivo metabolite identification. | Rapid communications in mass spectrometry : RCM 20070101 |
| Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy. | Reproductive toxicology (Elmsford, N.Y.) 20070101 |
| Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. | Antiviral therapy 20070101 |
| Efficacy, safety, and tolerability of long-term combination antiretroviral therapy in asymptomatic treatment-naïve adults with early HIV infection. | HIV clinical trials 20070101 |
| Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20070101 |
| Morphological and biochemical appraisal of the liver and renal effects of indinavir on rat pregnancy. | Clinical and experimental obstetrics & gynecology 20070101 |
| Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. | Antiviral therapy 20070101 |
| Indinavir crystalluria. | Kidney international 20061201 |
| Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. | Journal of leukocyte biology 20061101 |
| Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors. | Research in microbiology 20061101 |
| Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. | Blood 20061015 |
| Insulin sensitivity is preserved despite disrupted endothelial function. | American journal of physiology. Endocrinology and metabolism 20061001 |
| Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. | Clinical pharmacology and therapeutics 20061001 |
| Evaluation of an International Pharmacopoeia method for the analysis of indinavir sulfate by liquid chromatography. | Journal of pharmaceutical and biomedical analysis 20060911 |
| Effectiveness of low-dose indinavir/ritonavir at 400/100 mg twice a day with 2 nucleoside reverse transcriptase inhibitors in nonnucleoside reverse transcriptase inhibitor-experienced HIV-infected patients in India: 1-year follow-up. | Journal of acquired immune deficiency syndromes (1999) 20060901 |
| Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. | The Journal of infectious diseases 20060901 |
| Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. | Journal of pharmacokinetics and pharmacodynamics 20060801 |
| Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens. | The Journal of antimicrobial chemotherapy 20060801 |
| Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. | Journal of acquired immune deficiency syndromes (1999) 20060801 |
| Role of P-glycoprotein in tissue uptake of indinavir in rat. | Life sciences 20060801 |
| Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir. | Pharmaceutical research 20060801 |
| Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. | British journal of clinical pharmacology 20060801 |
| [Central nervous system HIV-associated polyarteritis nodosa: long-term outcome]. | La Revue de medecine interne 20060801 |
| Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe. | Pharmacotherapy 20060801 |
| Alcohol and indinavir adversely affect protein synthesis and phosphorylation of MAPK and mTOR signaling pathways in C2C12 myocytes. | Alcoholism, clinical and experimental research 20060801 |
| Urinary NO3 excretion and renal failure in indinavir-treated patients. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20060801 |
| High prevalence of indinavir-associated renal complications in Thai HIV-infected patients. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060801 |
| Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults. | European journal of medical research 20060630 |
| Gated binding of ligands to HIV-1 protease: Brownian dynamics simulations in a coarse-grained model. | Biophysical journal 20060601 |
| The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. | The Journal of antimicrobial chemotherapy 20060601 |
| Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy. | Clinical chemistry 20060601 |
| Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. | Journal of acquired immune deficiency syndromes (1999) 20060601 |
| Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. | Journal of molecular biology 20060519 |
| HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. | Apoptosis : an international journal on programmed cell death 20060501 |
| Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations. | The Journal of general virology 20060501 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. | Pharmacogenetics and genomics 20060501 |
| Electrochemical methods for determination of the protease inhibitor indinavir sulfate in pharmaceuticals and human serum. | Die Pharmazie 20060501 |
| Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. | AIDS (London, England) 20060424 |
| Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. | AIDS (London, England) 20060424 |
| Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis. | AIDS (London, England) 20060424 |
| Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060415 |
| [Drug-induced renal calculi]. | Annales d'urologie 20060401 |
| Indinavir-treated Cryptococcus neoformans promotes an efficient antifungal immune response in immunosuppressed hosts. | Medical mycology 20060301 |
| Simple and sensitive high-performance liquid chromatography method for the quantitation of indinavir in rat plasma and central nervous system. | Journal of separation science 20060301 |
| Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. | Journal of medicinal chemistry 20060223 |
| LC-MS/MS determination of the HIV-1 protease inhibitor indinavir in brain and testis of mice. | Journal of pharmaceutical and biomedical analysis 20060213 |
| [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection]. | Revista clinica espanola 20060201 |
| Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study. | AIDS (London, England) 20060102 |
| HIV protease inhibitors: suppression of insulin secretion by inhibition of voltage-dependent K+ currents and anion currents. | The Journal of pharmacology and experimental therapeutics 20060101 |
| Low urine pH is associated with reduced indinavir crystalluria in indinavir-treated HIV-infected individuals. | Clinical nephrology 20060101 |
| Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma. | In vivo (Athens, Greece) 20060101 |
| Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. | Basic & clinical pharmacology & toxicology 20060101 |
| T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. | BioTechniques 20060101 |
| Adhesive capsulitis of the shoulder in human immunodeficiency virus-positive patients during highly active antiretroviral therapy. | Journal of shoulder and elbow surgery 20060101 |
| Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). | Antiviral therapy 20060101 |
| Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. | Antiviral therapy 20060101 |
| [Pneumocystis jirovecii pneumonia: an old disease with a new name]. | Medicina (Kaunas, Lithuania) 20060101 |
| Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. | Antiviral therapy 20060101 |
| Quantitative SNP-detection method for estimating HIV-1 replicative fitness: application to protease inhibitor-resistant viruses. | Microbiology and immunology 20060101 |
| Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. | HIV clinical trials 20060101 |
| An immunological comparison of third companion in advanced drug-naive HIV-infected patients. | HIV clinical trials 20060101 |
| Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109). | Antiviral therapy 20060101 |
| Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. | AIDS (London, England) 20051202 |
| Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus. | Bioorganic & medicinal chemistry letters 20051201 |
| Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients. | Therapeutic drug monitoring 20051201 |
| Possible reduction in indinavir serum concentrations by bosentan. | Therapeutic drug monitoring 20051201 |
| Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux. | Die Pharmazie 20051201 |
| In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. | Drug metabolism and disposition: the biological fate of chemicals 20051101 |
| Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice. | Pharmaceutical research 20051101 |
| Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. | HIV medicine 20051101 |
| Indinavir impairs endothelial function in healthy HIV-negative men. | American heart journal 20051101 |
| HIV protease inhibitors block adipocyte differentiation independently of lamin A/C. | AIDS (London, England) 20051014 |
| Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. | The FEBS journal 20051001 |
| Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050915 |
| Indinavir alters regulators of protein anabolism and catabolism in skeletal muscle. | American journal of physiology. Endocrinology and metabolism 20050901 |
| Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. | British journal of clinical pharmacology 20050901 |
| Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. | Journal of acquired immune deficiency syndromes (1999) 20050901 |
| GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist-induced vascular reactivity in mouse aorta. | Arteriosclerosis, thrombosis, and vascular biology 20050801 |
| TDM: therapeutic drug measuring or therapeutic drug monitoring? | Therapeutic drug monitoring 20050801 |
| Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. | Clinical pharmacology and therapeutics 20050801 |
| Identification and characterization of a novel retroviral-like aspartic protease specifically expressed in human epidermis. | The Journal of investigative dermatology 20050801 |
| HIV associated arthritis: case report and review of the literature. | European journal of medical research 20050729 |
| Antileishmanial activity of HIV protease inhibitors. | International journal of antimicrobial agents 20050701 |
| Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. | AIDS (London, England) 20050701 |
| Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings. | Current HIV research 20050701 |
| Predicting drug metabolism--an evaluation of the expert system METEOR. | Chemistry & biodiversity 20050701 |
| [Consequences of replacing abacavir for indinavir in successful antiretroviral treatment of a patient with HIV infection]. | Presse medicale (Paris, France : 1983) 20050604 |
| [Outcome of HIV-infected patients after 5 years of antiretroviral therapy including a protease inhibitor: the Aproco/Copilote Cohort]. | Presse medicale (Paris, France : 1983) 20050604 |
| Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. | Annals of neurology 20050601 |
| Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. | The Journal of antimicrobial chemotherapy 20050601 |
| Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. | Journal of acquired immune deficiency syndromes (1999) 20050601 |
| Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. | Fundamental & clinical pharmacology 20050601 |
| Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073). | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050601 |
| Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor. | AIDS (London, England) 20050520 |
| Hepatotoxicity and nelfinavir: a meta-analysis. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20050501 |
| Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050415 |
| A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. | Neurology 20050412 |
| Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. | The Journal of antimicrobial chemotherapy 20050401 |
| Postexposure prophylaxis after sexual assaults: a prospective cohort study. | Sexually transmitted diseases 20050401 |
| Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. | Therapeutic drug monitoring 20050401 |
| Investigation of oral bioavailability and brain distribution of the Ind(8)-Val conjugate of indinavir in rodents. | The Journal of pharmacy and pharmacology 20050401 |
| Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics. | AIDS (London, England) 20050325 |
| Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. | European journal of clinical pharmacology 20050301 |
| Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081). | Journal of acquired immune deficiency syndromes (1999) 20050301 |
| Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir. | Journal of acquired immune deficiency syndromes (1999) 20050301 |
| Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. | Journal of clinical pharmacology 20050201 |
| Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort. | Therapeutic drug monitoring 20050201 |
| Dose reduction for the management of indinavir-related toxicity in human immunodeficiency virus type 1-infected patients in Taiwan: clinical and pharmacokinetic assessment. | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 20050201 |
| Warning about indinavir and pregnancy. | AIDS patient care and STDs 20050201 |
| Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. | Pharmacotherapy 20050201 |
| Influence of indinavir on virulence and growth of Cryptococcus neoformans. | The Journal of infectious diseases 20050115 |
| Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101 |
| HIV type 1 protease inhibitors enhance bone marrow progenitor cell activity in normal subjects and in HIV type 1-infected patients. | AIDS research and human retroviruses 20050101 |
| Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily. | HIV medicine 20050101 |
| [Radio-opaque lithiasis and indinavir]. | Actas urologicas espanolas 20050101 |
| Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. | Antiviral therapy 20050101 |
| Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. | Antiviral therapy 20050101 |
| The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life. | Health and quality of life outcomes 20050101 |
| Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. | Rapid communications in mass spectrometry : RCM 20050101 |
| HIV protease inhibitors prevent mitochondrial hyperpolarization and redox imbalance and decrease endogenous uncoupler protein-2 expression in gp 120-activated human T lymphocytes. | Antiviral therapy 20050101 |
| High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy. | Clinical pharmacokinetics 20050101 |
| Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes. | Antiviral therapy 20050101 |
| A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. | The Journal of biological chemistry 20041231 |
| Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? | Neurology 20041228 |
| A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20041215 |
| C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. | AIDS (London, England) 20041203 |
| Antiretrovirals as antimalarial agents. | The Journal of infectious diseases 20041201 |
| Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. | The Journal of endocrinology 20041201 |
| Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir. | Journal of molecular modeling 20041201 |
| Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats. | Die Pharmazie 20041201 |
| Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy. | Antiviral therapy 20041201 |
| Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial. | Clinical therapeutics 20041201 |
| Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. | AIDS (London, England) 20041119 |
| Residual analysis in linear regression models with an interval-censored covariate. | Statistics in medicine 20041115 |
| Indinavir impairs protein synthesis and phosphorylations of MAPKs in mouse C2C12 myocytes. | American journal of physiology. Cell physiology 20041101 |
| Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations. | Proteins 20041101 |
| Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. | Journal of acquired immune deficiency syndromes (1999) 20041101 |
| Optimization and statistical evaluation of dissolution tests for indinavir sulfate capsules. | Farmaco (Societa chimica italiana : 1989) 20041101 |
| Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. | AIDS research and human retroviruses 20041101 |
| Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells. | The Journal of infectious diseases 20041015 |
| Pseudoaneurysm of the femoral artery in a HIV-infected man. | European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20041001 |
| The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans. | FEMS immunology and medical microbiology 20041001 |
| Antiretroviral protease inhibitors prevent l6 muscle cell fusion by reducing calpain activity. | AIDS research and human retroviruses 20041001 |
| Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. | Biochemistry 20040928 |
| P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1. | Bioorganic & medicinal chemistry letters 20040920 |
| Indinavir increases glucose production in healthy HIV-negative men. | AIDS (London, England) 20040903 |
| Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20040901 |
| The ICH guidance in practice: stress degradation studies on indinavir sulphate and development of a validated specific stability-indicating HPTLC assay method. | Farmaco (Societa chimica italiana : 1989) 20040901 |
| In vitro and in vivo prevention of HIV protease inhibitor-induced insulin resistance by a novel small molecule insulin receptor activator. | Journal of cellular biochemistry 20040815 |
| HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040815 |
| Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. | Journal of virological methods 20040801 |
| Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. | The Journal of antimicrobial chemotherapy 20040801 |
| Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. | Infection 20040801 |
| Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040801 |
| Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. | American journal of obstetrics and gynecology 20040801 |
| ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. | Antiviral therapy 20040801 |
| [Drug-induced lithiasis]. | Revue medicale de la Suisse romande 20040801 |
| Nail, hair and skin hyperpigmentation associated with indinavir therapy. | AIDS (London, England) 20040723 |
| The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. | The Journal of clinical investigation 20040715 |
| Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040715 |
| Reversed-phase liquid chromatography with ultraviolet detection for simultaneous quantitation of indinavir and propranolol from ex-vivo rat intestinal permeability studies. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040705 |
| HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). | The Journal of pharmacology and experimental therapeutics 20040701 |
| Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. | HIV medicine 20040701 |
| Thrombosis and a hypercoagulable state in HIV-infected patients. | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20040701 |
| Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). | Current medical research and opinion 20040701 |
| Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. | Current medical research and opinion 20040701 |
| Direct interference of HIV protease inhibitors with pancreatic beta-cell function. | Naunyn-Schmiedeberg's archives of pharmacology 20040601 |
| The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. | Antiviral therapy 20040601 |
| [Highly Active AntiRetroviral Therapy and cryptosporidiosis]. | Parassitologia 20040601 |
| HIV protease inhibitors increase adiponectin levels in HIV-negative men. | Journal of acquired immune deficiency syndromes (1999) 20040501 |
| Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. | Pharmaceutical research 20040501 |
| Ritonavir boosted indinavir treatment as a simplified maintenance 'mono'-therapy for HIV infection. | AIDS (London, England) 20040409 |
| Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects. | Antiviral research 20040401 |
| Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. | European journal of biochemistry 20040401 |
| Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). | Antiviral therapy 20040401 |
| Lamivudine 300 mg in HIV infection: dose change. Once-a-day dosing. | Prescrire international 20040401 |
| Effect of indinavir used alone or in double or triple combination with AZT and ddC on human immune functions. | Life sciences 20040319 |
| Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? | The Journal of infectious diseases 20040315 |
| Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. | The Journal of infectious diseases 20040315 |
| Indinavir and rifabutin drug interactions in healthy volunteers. | Journal of clinical pharmacology 20040301 |
| Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040301 |
| Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks. | Chinese medical journal 20040301 |
| Spectrophotometric determination of indinavir in bulk and pharmaceutical formulations using bromocresol purple and bromothymol blue. | Die Pharmazie 20040301 |
| Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. | Journal of acquired immune deficiency syndromes (1999) 20040301 |
| Buffalo hump: what the experts suggest. | AIDS clinical care 20040301 |
| Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir. | International journal of antimicrobial agents 20040301 |
| Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART. | Antiviral research 20040301 |
| The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma. | International journal of cancer 20040210 |
| Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity. | Organic & biomolecular chemistry 20040207 |
| Capillary electrophoretic method for determination of protease inhibitor indinavir sulfate used in human immunodeficiency virus therapy. | Journal of pharmaceutical and biomedical analysis 20040204 |
| Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. | Brain : a journal of neurology 20040201 |
| Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040201 |
| Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir. | Analytical chemistry 20040201 |
| [Indinavir urolithiasis in HIV-positive patients. Treatment and prophylaxis]. | Der Urologe. Ausg. A 20040201 |
| Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions. | Antiviral therapy 20040201 |
| IDV concentrations plummet with rifampicin. | IAPAC monthly 20040201 |
| Relapsing blepharitis in patients under highly active antiretroviral therapy including indinavir. | AIDS (London, England) 20040123 |
| Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes by increasing levels of activated sterol regulatory element-binding proteins and decreasing cholesterol 7alpha-hydroxylase mRNA levels. | Biochemical pharmacology 20040115 |
| The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID. | Journal of acquired immune deficiency syndromes (1999) 20040101 |
| Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL). | HIV medicine 20040101 |
| Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. | Journal of molecular recognition : JMR 20040101 |
| Peptidomimetic inhibitors of HIV protease. | Current topics in medicinal chemistry 20040101 |
| Pharmacokinetics of indinavir in Koreans and Caucasians. | Scandinavian journal of infectious diseases 20040101 |
| Urologic problems in patients with acquired immunodeficiency syndrome. | TheScientificWorldJournal 20040101 |
| Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. | Cardiovascular toxicology 20040101 |
| Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy. | Cardiovascular toxicology 20040101 |
| [Indinavir and renal lithiasis]. | Actas urologicas espanolas 20040101 |
| HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. | Cardiovascular toxicology 20040101 |
| Urolithiasis associated with indinavir in a patient with spinal cord injury. | The journal of spinal cord medicine 20040101 |
| HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. | Cardiovascular toxicology 20040101 |
| Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. | Biochemistry 20031230 |
| Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. | Journal of medicinal chemistry 20031218 |
| Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20031215 |
| TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. | AIDS (London, England) 20031205 |
| Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. | Journal of acquired immune deficiency syndromes (1999) 20031201 |
| No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. | British journal of clinical pharmacology 20031201 |
| Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults. | Therapeutic drug monitoring 20031201 |
| Photophobia in a patient with high indinavir plasma concentrations. | Therapeutic drug monitoring 20031201 |
| A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. | Antiviral therapy 20031201 |
| Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. | Antiviral therapy 20031201 |
| HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. | The Journal of biological chemistry 20031128 |
| Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. | AIDS (London, England) 20031121 |
| Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir. | Bioorganic & medicinal chemistry letters 20031117 |
| Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups. | European journal of medical research 20031112 |
| Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. | AIDS (London, England) 20031107 |
| Influence of goldenseal root on the pharmacokinetics of indinavir. | Journal of clinical pharmacology 20031101 |
| Field evaluation of an improved assay using a heat-dissociated p24 antigen for adults mainly infected with HIV-1 CRF02_AG strains in Côte d'Ivoire, West Africa. | Journal of acquired immune deficiency syndromes (1999) 20031101 |
| Treating advanced HIV infection. | Journal of acquired immune deficiency syndromes (1999) 20031101 |
| The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: a pilot study. | International journal of STD & AIDS 20031101 |
| A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure. | AIDS research and human retroviruses 20031101 |
| [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir]. | Medicina clinica 20031025 |
| Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation. | AIDS (London, England) 20031017 |
| Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031015 |
| Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. | Biochemical pharmacology 20031015 |
| [Interaction between methadone and antiretrovirals (stavudine, indinavir, ritonavir, nevirapine)]. | Medicina clinica 20031004 |
| Changes in indinavir exposure over time: a case study in six HIV-1-infected children. | The Journal of antimicrobial chemotherapy 20031001 |
| Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20031001 |
| Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults. | Therapeutic drug monitoring 20031001 |
| Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. | HIV medicine 20031001 |
| Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. | Journal of acquired immune deficiency syndromes (1999) 20031001 |
| A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study). | Antiviral therapy 20031001 |
| Anti-HIV agents. High-dose vitamin C may affect indinavir users. | TreatmentUpdate 20031001 |
| Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures. | AIDS (London, England) 20030905 |
| Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. | AIDS (London, England) 20030905 |
| A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. | The Journal of infectious diseases 20030901 |
| Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. | The Journal of infectious diseases 20030901 |
| The HIV protease inhibitor indinavir reduces immature dendritic cell transendothelial migration. | European journal of immunology 20030901 |
| Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030901 |
| The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells. | The Journal of endocrinology 20030901 |
| Overdose reports--an underutilized resource. | Pharmacoepidemiology and drug safety 20030901 |
| A five-year evaluation of reports of overdose with indinavir sulfate. | Pharmacoepidemiology and drug safety 20030901 |
| Boosted PIs: competition hots up. | The AIDS reader 20030901 |
| Characterizing classes of antiretroviral drugs by genotype. | Statistics in medicine 20030830 |
| Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. | Annals of internal medicine 20030819 |
| Summaries for patients. Does marijuana affect viral loads in people with HIV? | Annals of internal medicine 20030819 |
| Virological rebound after suppression on highly active antiretroviral therapy. | AIDS (London, England) 20030815 |
| HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent. | Bioorganic & medicinal chemistry letters 20030804 |
| The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains. | Bioorganic & medicinal chemistry letters 20030804 |
| Push/pull mechanisms of GLUT4 traffic in muscle cells. | Acta physiologica Scandinavica 20030801 |
| Vasodilator agents protect against indinavir nephrotoxicity. | Antiviral therapy 20030801 |
| Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. | Antiviral therapy 20030801 |
| Sequential cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis. | AIDS (London, England) 20030725 |
| Joint models for efficient estimation in proportional hazards regression models. | Statistics in medicine 20030715 |
| Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. | International journal for parasitology 20030701 |
| HIV protease inhibitors acutely impair glucose-stimulated insulin release. | Diabetes 20030701 |
| Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up. | HIV medicine 20030701 |
| Coadministration of milk thistle and indinavir in healthy subjects. | Pharmacotherapy 20030701 |
| Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. | AIDS (London, England) 20030701 |
| Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. | Journal of immunology (Baltimore, Md. : 1950) 20030615 |
| A review of low-dose ritonavir in protease inhibitor combination therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030615 |
| Latrogenic nephrogenic diabetes insipidus. | AIDS (London, England) 20030613 |
| Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. | Therapeutic drug monitoring 20030601 |
| Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. | Therapeutic drug monitoring 20030601 |
| Cholelithiasis possibly induced by protease inhibitors in 3 patients. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030601 |
| Assessment of adherence to triple antiretroviral treatment including indinavir: role of the determination of plasma levels of indinavir. | Journal of acquired immune deficiency syndromes (1999) 20030601 |
| Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys. | Xenobiotica; the fate of foreign compounds in biological systems 20030601 |
| Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure. | AIDS research and human retroviruses 20030601 |
| Nucleoside-free regimen tested. | AIDS patient care and STDs 20030601 |
| Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics. | Antiviral therapy 20030601 |
| Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. | AIDS (London, England) 20030523 |
| Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. | AIDS (London, England) 20030523 |
| Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. | AIDS (London, England) 20030523 |
| A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. | AIDS (London, England) 20030502 |
| High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors. | AIDS (London, England) 20030502 |
| Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. | The Journal of antimicrobial chemotherapy 20030501 |
| Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues. | Diabetologia 20030501 |
| Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. | Chemotherapy 20030501 |
| Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. | AIDS patient care and STDs 20030501 |
| [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy]. | Anales de medicina interna (Madrid, Spain : 1984) 20030501 |
| In-vitro crystallization of indinavir in the presence of ritonavir and as a function of pH. | The Journal of pharmacy and pharmacology 20030501 |
| [Managing side effects. Individualized dosage makes indinavir more tolerable]. | MMW Fortschritte der Medizin 20030428 |
| Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. | Neurology 20030422 |
| Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. | AIDS (London, England) 20030411 |
| Sildenafil does not alter nelfinavir pharmacokinetics. | Therapeutic drug monitoring 20030401 |
| Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. | The Journal of infectious diseases 20030401 |
| [Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV]. | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 20030401 |
| HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. | AIDS (London, England) 20030307 |
| Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. | Clinical pharmacology and therapeutics 20030301 |
| Indinavir-induced thrombocytopenia. | AIDS patient care and STDs 20030301 |
| Inference for a linear regression model with an interval-censored covariate. | Statistics in medicine 20030215 |
| Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. | Journal of acquired immune deficiency syndromes (1999) 20030201 |
| Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats. | Biological & pharmaceutical bulletin 20030201 |
| The HIV protease inhibitor indinavir impairs glycogen synthesis in HepG2 hepatoma cells. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20030201 |
| Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy. | International journal of STD & AIDS 20030201 |
| [Antiretrovirals]. | Nihon rinsho. Japanese journal of clinical medicine 20030201 |
| Anti-retroviral protease inhibitors--'a two edged sword?'. | IUBMB life 20030201 |
| [HIV protease inhibitors for the treatment of Kaposi's sarcoma]. | Recenti progressi in medicina 20030201 |
| A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. | Biochemistry 20030128 |
| Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors. | European journal of medical research 20030128 |
| Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. | AIDS (London, England) 20030124 |
| Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. | AIDS (London, England) 20030103 |
| Predicting HIV drug resistance with neural networks. | Bioinformatics (Oxford, England) 20030101 |
| The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling. | Journal of lipid research 20030101 |
| 'Multi-component reactions : emerging chemistry in drug discovery' 'from xylocain to crixivan'. | Current medicinal chemistry 20030101 |
| Overcoming resistance: virologic response to a salvage regimen with the combination of ritonavir plus indinavir. | HIV clinical trials 20030101 |
| Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. | HIV clinical trials 20030101 |
| Analysis of the pH-dependencies of the association and dissociation kinetics of HIV-1 protease inhibitors. | Journal of molecular recognition : JMR 20030101 |
| Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials. | Pharmacoepidemiology and drug safety 20030101 |
| Differences in durability of treatment with initial PI-based regimens. | HIV clinical trials 20030101 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drinking lots of water still necessary with new indinavir regimens. | TreatmentUpdate 20030101 |
| Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir. | Journal of acquired immune deficiency syndromes (1999) 20021215 |
| Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. | Journal of acquired immune deficiency syndromes (1999) 20021215 |
| Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen. | Journal of acquired immune deficiency syndromes (1999) 20021215 |
| Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. | AIDS (London, England) 20021206 |
| Post-exposure prophylaxis. | International journal of STD & AIDS 20021201 |
| Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. | AIDS (London, England) 20021122 |
| Underpowered clinical trials of antiretroviral treatment. | JAMA 20021106 |
| Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021101 |
| Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. | Diabetes 20021101 |
| Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O. | Journal of clinical microbiology 20021101 |
| Cutaneous EBV-related lymphoproliferative disorder in a 15-year-old boy with AIDS: an unusual clinical presentation. | Journal of pediatric hematology/oncology 20021101 |
| Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers. | Pharmaceutical research 20021101 |
| Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data. | Pathologie-biologie 20021101 |
| Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'. | Bioorganic & medicinal chemistry letters 20021021 |
| Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. | AIDS (London, England) 20021018 |
| Rash-associated severe neutropenia as a side-effect of indinavir in HIV postexposure prophylaxis. | AIDS (London, England) 20021018 |
| Structural elucidation of metabolites of ritonavir and indinavir by liquid chromatography-mass spectrometry. | Journal of chromatography. A 20021018 |
| Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS. | Journal of pharmaceutical and biomedical analysis 20021015 |
| Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy. | Annals of internal medicine 20021015 |
| Hair it is: the long and short of monitoring antiretroviral treatment. | Annals of internal medicine 20021015 |
| Summaries for patients. The relationship between levels of the anti-HIV drug indinavir in patients' hair and response to treatment. | Annals of internal medicine 20021015 |
| Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. | Journal of clinical pharmacology 20021001 |
| Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. | Journal of virological methods 20021001 |
| Type B lactic acidosis: a rare complication of antiretroviral therapy after cardiac surgery. | The Annals of thoracic surgery 20021001 |
| Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. | HIV medicine 20021001 |
| First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. | HIV medicine 20021001 |
| Indirect hyperbilirubinemia with indinavir. | The Journal of the Association of Physicians of India 20021001 |
| [Antiretroviral therapy with nelfinavir for patient infected, by HIV and secondary diabetes mellitus due to indinavir]. | Medicina clinica 20020928 |
| Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. | AIDS (London, England) 20020927 |
| Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains. | Bioorganic & medicinal chemistry letters 20020902 |
| Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains. | Bioorganic & medicinal chemistry letters 20020902 |
| Indinavir-induced cholelithiasis in a patient infected with human immunodeficiency virus. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020901 |
| Need for GLUT4 activation to reach maximum effect of insulin-mediated glucose uptake in brown adipocytes isolated from GLUT4myc-expressing mice. | Diabetes 20020901 |
| The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. | British journal of clinical pharmacology 20020901 |
| Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity. | Antiviral therapy 20020901 |
| [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management]. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20020901 |
| Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. | AIDS (London, England) 20020816 |
| Generalized hair loss induced by indinavir plus ritonavir therapy. | AIDS (London, England) 20020816 |
| Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020805 |
| Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting. | Therapeutic drug monitoring 20020801 |
| Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. | Pediatrics 20020801 |
| Engineering an indene bioconversion process for the production of cis-aminoindanol: a model system for the production of chiral synthons. | Applied microbiology and biotechnology 20020801 |
| Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. | Clinical pharmacology and therapeutics 20020801 |
| Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. | The Pediatric infectious disease journal 20020801 |
| Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. | JAMA 20020710 |
| Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. | Biochemistry 20020709 |
| Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. | Archives of internal medicine 20020708 |
| Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance. | Proteins 20020701 |
| Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. | Journal of acquired immune deficiency syndromes (1999) 20020701 |
| Immunophenotypic analyses of CD34(+) cell subsets in bone marrow from HIV-infected patients during highly- active antiretroviral therapy. | European journal of clinical investigation 20020701 |
| High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. | Therapeutic drug monitoring 20020601 |
| Urinary cytology associated with human polyomavirus and indinavir therapy in HIV-infected patients. | American journal of clinical pathology 20020601 |
| Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. | Antiviral therapy 20020601 |
| Select HIV protease inhibitors alter bone and fat metabolism ex vivo. | The Journal of biological chemistry 20020531 |
| A neutravidin-based assay for reverse transcriptase suitable for high throughput screening of retroviral activity. | Journal of biochemistry and molecular biology 20020531 |
| Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. | The Journal of pharmacology and experimental therapeutics 20020501 |
| Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. | The Annals of pharmacotherapy 20020501 |
| Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. | Pharmacotherapy 20020501 |
| Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: a case report. | American journal of hypertension 20020501 |
| Male sexual dysfunction associated with antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20020501 |
| Bone mineral density abnormalities in patients with HIV infection. | Journal of acquired immune deficiency syndromes (1999) 20020501 |
| [Ureteral lithiasis caused by Indinavir]. | Revista medica de Chile 20020501 |
| Sarcoidosis and interstitial nephritis in a child with acquired immunodeficiency syndrome: implications of immune reconstitution syndrome with an indinavir-based regimen. | The Pediatric infectious disease journal 20020501 |
| AIDS-related primary central nervous system lymphoma: prolonged remission associated with highly active antiretroviral therapy. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20020501 |
| A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. | Journal of medicinal chemistry 20020425 |
| Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020415 |
| Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. | AIDS (London, England) 20020412 |
| HIV protease inhibitors and glucose metabolism. | AIDS (London, England) 20020412 |
| [A plea for an individualized therapy regimen. Which is the optimal dose?]. | MMW Fortschritte der Medizin 20020409 |
| [More transparency facilities drug choice in general practice. Booster regimens in direct comparison]. | MMW Fortschritte der Medizin 20020409 |
| Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020401 |
| Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography. | Therapeutic drug monitoring 20020401 |
| Indinavir induces acute and reversible peripheral insulin resistance in rats. | Diabetes 20020401 |
| High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. | Journal of acquired immune deficiency syndromes (1999) 20020401 |
| Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. | The Annals of pharmacotherapy 20020401 |
| CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. | Clinical pharmacology and therapeutics 20020401 |
| [Post-exposure prophylaxis in Zambia; the experiences of a tropical disease specialist following a cut accidentally incurred while operating on an HIV positive patient]. | Nederlands tijdschrift voor geneeskunde 20020330 |
| The human 26S proteasome is a target of antiretroviral agents. | AIDS (London, England) 20020329 |
| Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. | AIDS (London, England) 20020329 |
| The utility of inhibitory quotients in determining the relative potency of protease inhibitors. | AIDS (London, England) 20020329 |
| Osteosclerosis and periostal new bone formation during indinavir therapy. | AIDS (London, England) 20020329 |
| Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. | AIDS (London, England) 20020329 |
| The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. | AIDS (London, England) 20020308 |
| Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. | AIDS (London, England) 20020308 |
| Final analysis of the Trilège induction-maintenance trial: results at 18 months. | AIDS (London, England) 20020308 |
| Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. | AIDS (London, England) 20020308 |
| [Acute coronary syndromes in patients treated with HIV protease inhibitors]. | Presse medicale (Paris, France : 1983) 20020302 |
| Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes. | Journal of virology 20020301 |
| HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. | Nature medicine 20020301 |
| Characterizing the relationship between HIV-1 genotype and phenotype: prediction-based classification. | Biometrics 20020301 |
| A combinatorial library of indinavir analogues and its in vitro and in vivo studies. | Bioorganic & medicinal chemistry letters 20020225 |
| A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. | Brain research 20020215 |
| Reduction of HIV-1 viral load in saliva by indinavir-containing antiretroviral regimen. | AIDS (London, England) 20020215 |
| Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. | Biochimica et biophysica acta 20020201 |
| Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. | Protein science : a publication of the Protein Society 20020201 |
| Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. | Pediatrics 20020201 |
| In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats. | The Journal of pharmacy and pharmacology 20020201 |
| Efficacy of highly active antiretroviral therapy in HIV-1 infected children. | The Lancet. Infectious diseases 20020201 |
| [A clinical trial using zidovudine and lamivudine plus indinavir triple therapy in Chinese individuals with human immunodeficiency virus infection]. | Zhonghua nei ke za zhi 20020201 |
| Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression. | AIDS (London, England) 20020125 |
| Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. | AIDS (London, England) 20020125 |
| Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. | AIDS research and human retroviruses 20020120 |
| [Advances in the domain of HIV]. | Presse medicale (Paris, France : 1983) 20020119 |
| Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. | AIDS (London, England) 20020104 |
| Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. | The Journal of infectious diseases 20020101 |
| Rheumatological complications associated with the use of indinavir and other protease inhibitors. | Annals of the rheumatic diseases 20020101 |
| Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? | Journal of acquired immune deficiency syndromes (1999) 20020101 |
| The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. | The Journal of endocrinology 20020101 |
| Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor. | American journal of clinical dermatology 20020101 |
| Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. | HIV clinical trials 20020101 |
| The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. | Clinical pharmacology and therapeutics 20020101 |
| CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. | Xenobiotica; the fate of foreign compounds in biological systems 20020101 |
| Epidural lipomatosis secondary to indinavir in an HIV-positive patient. | Clinical neuropharmacology 20020101 |
| Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART. | Infection 20020101 |
| Interaction between levothyroxine and indinavir in a patient with HIV infection. | Infection 20020101 |
| HIV postexposure prophylaxis in the remote prehospital environment. | Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors 20020101 |
| The role of pharmacokinetics in drug discovery: finding drug candidates with the greatest potential for success. | Ernst Schering Research Foundation workshop 20020101 |
| Successful simplification of HAART in patients with acute primary HIV infection. | Journal of biological regulators and homeostatic agents 20020101 |
| Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. | HIV medicine 20020101 |
| A critical evaluation of the therapeutic range of indinavir. | The Annals of pharmacotherapy 20020101 |
| Evaluation of the origins of the selectivity of polymers imprinted with a HIV protease inhibitor using infrared spectroscopy and high performance liquid chromatography. | Enantiomer 20020101 |
| Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats. | Antiviral chemistry & chemotherapy 20020101 |
| Immune reconstitution during intensive chemotherapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma. | The hematology journal : the official journal of the European Haematology Association 20020101 |
| [Prophylactic antiretroviral therapy after sexual exposure to HIV: 93 cases]. | Annales de dermatologie et de venereologie 20020101 |
| Toxicity. Milk thistle and indinavir. | TreatmentUpdate 20020101 |
| Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients. | HIV clinical trials 20020101 |
| Indinavir-induced retinoid-like effects: incidence, clinical features and management. | Drug safety 20020101 |
| [Drug-induced acute pancreatitis: a personal contribution]. | Chirurgia italiana 20020101 |
| Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. | HIV clinical trials 20020101 |
| Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients. | International urology and nephrology 20020101 |
| [Renal lithiasis due to indinavir]. | Revista de medicina de la Universidad de Navarra 20020101 |
| Antiretroviral therapy 2002: old and new paradigms. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20020101 |
| Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. | The Journal of biological chemistry 20011221 |
| Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. | Annals of internal medicine 20011204 |
| Summaries for patients. Predictors of outcomes in patients with HIV infection treated with indinavir, zidovudine, and lamivudine. | Annals of internal medicine 20011204 |
| The chemotherapeutic agent bleomycin in a two-drug combination with zidovudine, ritonavir or indinavir synergistically inhibits HIV Type-1 replication in peripheral blood lymphocytes. | International journal of antimicrobial agents 20011201 |
| Reduction of signal suppression effects in ESI-MS using a nanosplitting device. | Analytical chemistry 20011201 |
| Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy? | European psychiatry : the journal of the Association of European Psychiatrists 20011201 |
| [Urinary lithiasis secondary to indinavir in an HIV-positive patient]. | Archivos espanoles de urologia 20011201 |
| Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study). | Antiviral therapy 20011201 |
| Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. | Lancet (London, England) 20011124 |
| Protease inhibitors and erectile dysfunction. | AIDS (London, England) 20011123 |
| HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells. | AIDS (London, England) 20011123 |
| Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir. | Carbohydrate research 20011121 |
| Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases. | AIDS research and human retroviruses 20011120 |
| Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo. | The Journal of infectious diseases 20011115 |
| Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. | The Journal of infectious diseases 20011101 |
| Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures. | Drug and alcohol dependence 20011101 |
| Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. | Laboratory investigation; a journal of technical methods and pathology 20011101 |
| Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen. | The Annals of pharmacotherapy 20011101 |
| Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20011001 |
| Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. | Archives of internal medicine 20010910 |
| Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. | AIDS (London, England) 20010907 |
| Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. | AIDS (London, England) 20010907 |
| Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. | The Journal of antimicrobial chemotherapy 20010901 |
| Incidence and risk factors for the development of indinavir-associated renal complications. | The Journal of antimicrobial chemotherapy 20010901 |
| Application of radiolabeled tracers to biocatalytic flux analysis. | European journal of biochemistry 20010901 |
| Indinavir crystallization around the loop of Henle: experimental evidence. | Journal of acquired immune deficiency syndromes (1999) 20010901 |
| Different combinations of ritonavir-indinavir. | TreatmentUpdate 20010901 |
| Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir. | Antiviral therapy 20010901 |
| A case of flare syndrome. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20010901 |
| Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials. | AIDS (London, England) 20010817 |
| HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. | Journal of acquired immune deficiency syndromes (1999) 20010801 |
| Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. | Journal of the American Chemical Society 20010801 |
| Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. | Therapeutic drug monitoring 20010801 |
| Papillary necrosis associated with the HIV protease inhibitor indinavir. | Infection 20010801 |
| Antiretroviral rounds. When success is a pain. | AIDS clinical care 20010801 |
| [Paronychia in patients infected with HIV treated with indinavir]. | Revista clinica espanola 20010801 |
| P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? | AIDS (London, England) 20010727 |
| Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. | AIDS (London, England) 20010727 |
| Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. | AIDS (London, England) 20010727 |
| Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS. | The Journal of infectious diseases 20010715 |
| The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. | Blood 20010715 |
| High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction. | Journal of chromatography. B, Biomedical sciences and applications 20010715 |
| Prevalence and predictive value of intermittent viremia with combination hiv therapy. | JAMA 20010711 |
| Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. | AIDS (London, England) 20010706 |
| P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. | The Journal of pharmacology and experimental therapeutics 20010701 |
| CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART. | The British journal of ophthalmology 20010701 |
| In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide). | British journal of clinical pharmacology 20010701 |
| A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. | Journal of acquired immune deficiency syndromes (1999) 20010701 |
| HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. | FEMS immunology and medical microbiology 20010701 |
| Recent advances in the management and treatment of GI and hepatic diseases associated with HIV: Part I. | The AIDS reader 20010701 |
| Indinavir and bones: does thickness = strength? | TreatmentUpdate 20010701 |
| Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. | Journal of chromatography. B, Biomedical sciences and applications 20010615 |
| Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010601 |
| The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. | Diabetes 20010601 |
| The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. | Diabetes 20010601 |
| Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20010601 |
| Limited sampling approach. | Clinical pharmacology and therapeutics 20010601 |
| The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients. | Journal of the American Dietetic Association 20010601 |
| Once-a-day indinavir studied. | AIDS patient care and STDs 20010601 |
| Background on glucose--from food to blood sugar. | TreatmentUpdate 20010601 |
| Indinavir--effect on sugar and insulin. | TreatmentUpdate 20010601 |
| Protease inhibitors and blood sugar problems. | TreatmentUpdate 20010601 |
| Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. | AIDS (London, England) 20010525 |
| Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. | AIDS (London, England) 20010525 |
| 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. | AIDS (London, England) 20010525 |
| Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy. | AIDS (London, England) 20010525 |
| Is indinavir crystalluria an indicator for indinavir stone formation? | AIDS (London, England) 20010525 |
| Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography. | Journal of chromatography. B, Biomedical sciences and applications 20010505 |
| [Effective in HIV: dual combination with indinavir and ritonavir]. | Deutsche medizinische Wochenschrift (1946) 20010504 |
| Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance. | AIDS (London, England) 20010504 |
| Metabolic effects of indinavir in healthy HIV-seronegative men. | AIDS (London, England) 20010504 |
| An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma. | Journal of pharmaceutical and biomedical analysis 20010501 |
| Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. | The Journal of infectious diseases 20010501 |
| Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. | Endocrinology 20010501 |
| Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization. | AIDS research and human retroviruses 20010501 |
| [Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV]. | Presse medicale (Paris, France : 1983) 20010421 |
| Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010415 |
| Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. | Analytical biochemistry 20010415 |
| Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. | AIDS (London, England) 20010413 |
| Indinavir and systemic hypertension. | AIDS (London, England) 20010413 |
| Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. | The Journal of infectious diseases 20010401 |
| Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells. | The Journal of antimicrobial chemotherapy 20010401 |
| Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. | Journal of clinical pharmacology 20010401 |
| Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1. | Molecular therapy : the journal of the American Society of Gene Therapy 20010401 |
| CT appearances of HIV-related lipodystrophy syndrome. | The British journal of radiology 20010401 |
| Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. | The Journal of infection 20010401 |
| Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. | AIDS (London, England) 20010330 |
| Competition prompts drug companies to cut antiretroviral drug prices. | Lancet (London, England) 20010317 |
| Anti-AIDS drugs available 'at cost'. | Nature 20010315 |
| Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier. | AIDS (London, England) 20010309 |
| Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. | JAMA 20010307 |
| Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. | The Journal of infectious diseases 20010301 |
| Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy. | The Journal of infectious diseases 20010301 |
| Resolution of microsporidial keratoconjunctivitis in an AIDS patient treated with highly active antiretroviral therapy. | American journal of ophthalmology 20010301 |
| A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. | Journal of acquired immune deficiency syndromes (1999) 20010301 |
| The safety and antiviral effect of protease inhibitors in children. | Pharmacotherapy 20010301 |
| Effect of indinavir on the pharmacokinetics of rifampicin in HIV-infected patients. | The Journal of pharmacy and pharmacology 20010301 |
| HIV/AIDS case histories: indinavir crystalluria. | AIDS patient care and STDs 20010301 |
| Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial. | Antiviral therapy 20010301 |
| Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. | The Journal of infectious diseases 20010201 |
| Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients. | International journal of antimicrobial agents 20010201 |
| Association between high serum prolactin levels and concomitant infections in HIV-infected patients. | Human immunology 20010201 |
| Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography. | Therapeutic drug monitoring 20010201 |
| [Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy]. | Annales de medecine interne 20010201 |
| [Acute porphyria and indinavir]. | Annales de dermatologie et de venereologie 20010201 |
| Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20010201 |
| [Resistance to protease inhibitors]. | Enfermedades infecciosas y microbiologia clinica 20010201 |
| The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. | AIDS (London, England) 20010126 |
| Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. | AIDS research and human retroviruses 20010120 |
| Indinavir, zidovudine, lamivudine: 3-year follow-up. | Annals of internal medicine 20010116 |
| Changes in host cell molecules acquired by circulating HIV-1 in patients treated with highly active antiretroviral therapy and interleukin-2. | AIDS (London, England) 20010105 |
| Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. | AIDS (London, England) 20010105 |
| Paronychia in association with indinavir treatment. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010101 |
| Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. | Antimicrobial agents and chemotherapy 20010101 |
| Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. | British journal of clinical pharmacology 20010101 |
| The absence of hyperbilirubinaemia is highly predictive of treatment failure in advanced HIV-infected patients treated with indinavir. | International journal of STD & AIDS 20010101 |
| Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy. | PharmacoEconomics 20010101 |
| [Bilateral hip necrosis, corticoids, and human immunodeficiency virus protease inhibitors]. | Enfermedades infecciosas y microbiologia clinica 20010101 |
| [Simultaneous quantitative determination of amprenavir and indinavir in human plasma by high-performance liquid chromatography]. | Annales de biologie clinique 20010101 |
| Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. | Scandinavian journal of infectious diseases 20010101 |
| Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy. | The Annals of pharmacotherapy 20010101 |
| [AIDS, activism, and the regulation of clinical trials in Brazil: Protocol 028]. | Cadernos de saude publica 20010101 |
| Effects of interleukin-2 therapy on the proliferation and differentiation of CD4/CD25 positive and CD4/CD25 negative cells in HIV+ patients. | European cytokine network 20010101 |
| Ritonavir and indinavir one year later. | TreatmentUpdate 20010101 |
| Using ritonavir with indinavir in cases of virologic failure. | TreatmentUpdate 20010101 |
| Merck pushes the envelope with once-daily indinavir. | TreatmentUpdate 20010101 |
| Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations. | HIV clinical trials 20010101 |
| Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC. | Clinical laboratory 20010101 |
| Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study. | HIV clinical trials 20010101 |
| Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. | HIV medicine 20010101 |
| Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. | Journal of molecular graphics & modelling 20010101 |
| Sugar blues and protease inhibitors. | TreatmentUpdate 20010101 |
| [Nephropathy caused by crystal deposits induced by indinavir]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20010101 |
| [Nephrolithiasis in a HIV infected patient treated with indinavir]. | Przeglad lekarski 20010101 |
| In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. | Journal of human virology 20010101 |
| A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. | Psychopharmacology bulletin 20010101 |
| Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. | The Journal of urology 20001201 |
| Symptomatic crystalluria associated with indinavir. | The Annals of pharmacotherapy 20001201 |
| Leucocytoclastic vasculitis and indinavir. | The British journal of dermatology 20001101 |
| Sudden anuria due to indinavir crystalluria. | Nephron 20001101 |
| Pyuria in patients treated with indinavir is associated with renal dysfunction. | Clinical nephrology 20001001 |
| [Anuria in HIV+ patients treated with indinavir]. | Archivos espanoles de urologia 20001001 |
| Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors. | Journal of medicinal chemistry 20000907 |
| Sudden unexpected death as a consequence of indinavir-induced nephropathy. A case report. | APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20000901 |
| 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. | Annals of internal medicine 20000704 |
| Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. | Antiviral chemistry & chemotherapy 20000701 |
| Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir. | Biochemical pharmacology 20000501 |
| Indinavir calculi: diagnosis with magnetic resonance urography. | European urology 20000501 |
| In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii. | The Journal of infectious diseases 20000501 |
| Urinary cytology changes in protease inhibitor induced urolithiasis. | The Journal of urology 20000401 |
| Acute tubulointerstitial nephritis attributable to indinavir therapy. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20000401 |
| Severe hypertension and renal atrophy associated with indinavir. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20000301 |
| Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir. | Antiviral chemistry & chemotherapy 20000301 |
| Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. | Antiviral therapy 20000301 |
| A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients. | AIDS (London, England) 20000128 |
| [Hemolytic anemia associated with indinavir administration]. | Enfermedades infecciosas y microbiologia clinica 19991101 |
| Treatment for human immunodeficiency virus with indinavir may cause relevant urological side-effects, effectively treatable by rehydration. | BJU international 19991001 |
| Failure of indinavir to inhibit Candida albicans in vitro. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19991001 |
| Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. | The Journal of biological chemistry 19990820 |
| In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. | The Journal of infectious diseases 19990801 |
| Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19990801 |
| Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. | The Journal of urology 19990601 |
| [Treatment of complicated renal colic in patients treated with indinavir: value of double J stents]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 19990601 |
| Urolithiasis associated with protease inhibitors. | Journal of endourology 19990501 |
| Acute renal failure caused by indinavir in a patient with a single functioning kidney. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19990501 |
| Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19990501 |
| Haemolytic anaemia associated with indinavir. | Postgraduate medical journal 19990501 |
| Images in clinical medicine. Indinavir crystalluria. | The New England journal of medicine 19990429 |
| Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. | The Journal of urology 19990401 |
| Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. | AIDS (London, England) 19990311 |
| Indinavir-induced nephropathy. | Clinical nephrology 19990301 |
| [Indinavir-induced anuria]. | Revista clinica espanola 19990301 |
| Case no. 3. Right flank pain. Crixivan lithiasis. | Techniques in urology 19990301 |
| [Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients]. | Presse medicale (Paris, France : 1983) 19990227 |
| Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. | Antimicrobial agents and chemotherapy 19990201 |
| Persistent flank pain, low-grade fever, and malaise in a woman treated with indinavir. | AIDS patient care and STDs 19990201 |
| [Hydronephrosis caused by indinavir]. | Enfermedades infecciosas y microbiologia clinica 19990101 |
| Urolithiasis and the protease inhibitor indinavir. | European urology 19990101 |
| Changes in renal function associated with indinavir. | AIDS (London, England) 19981224 |
| Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. | AIDS (London, England) 19981224 |
| Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. | AIDS (London, England) 19981224 |
| Persistent nephrolithiasis after discontinuation of indinavir therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19981201 |
| [Clinical case of the month. Apropos of pancytopenia in a seropositive patient]. | Revue medicale de Liege 19981201 |
| Rapid development of indinavir-induced asymptomatic crystalluria in a human immunodeficiency virus-negative patient. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19981001 |
| Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy. | AJR. American journal of roentgenology 19980901 |
| Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. | Clinical nephrology 19980901 |
| New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. | Journal of medicinal chemistry 19980827 |
| Crystalluria and urinary tract abnormalities associated with indinavir. | The Journal of urology 19980801 |
| Ureteral obstruction secondary to indinavir in the pediatric HIV population. | Pediatric radiology 19980801 |
| Nephrolithiasis from indinavir, a new human immunodeficiency virus drug. | The Journal of urology 19980601 |
| Subtle occurrence of indinavir-induced acute renal insufficiency. | AIDS (London, England) 19980528 |
| Selected highlights on women and HIV from the 5th Conference on Retroviruses and Opportunistic Infections. | BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 19980401 |
| [Nephritic colic due to indinavir]. | Presse medicale (Paris, France : 1983) 19980314 |
| Indinavir-induced renal failure. | AIDS (London, England) 19980305 |
| Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. | Archives of pathology & laboratory medicine 19980301 |
| Indinavir and interstitial nephritis. | Annals of internal medicine 19980215 |
| Anuria and acute renal failure resulting from indinavir sulfate induced nephrolithiasis. | The Journal of urology 19980201 |
| Indinavir-associated hepatitis in patients with advanced HIV infection. | International journal of STD & AIDS 19980101 |
| Acute interstitial nephritis secondary to the administration of indinavir. | The Annals of pharmacotherapy 19980101 |
| The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor. | Pharmaceutical biotechnology 19980101 |
| [Urinary calculi and crystalluria in HIV+ patients treated with indinavir sulfate]. | Presse medicale (Paris, France : 1983) 19971108 |
| Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor. | AIDS (London, England) 19971101 |
| [Hemolytic jaundice related to ingestion of indinavir]. | Presse medicale (Paris, France : 1983) 19971101 |
| Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. | American journal of kidney diseases : the official journal of the National Kidney Foundation 19971001 |
| Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection. | The Annals of pharmacotherapy 19971001 |
| Protease inhibitor-induced urolithiasis. | Urology 19971001 |
| Urolithiasis associated with the protease inhibitor indinavir. | Urology 19971001 |
| Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. | Journal of virology 19970901 |
| An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex. | Journal of medicinal chemistry 19970801 |
| Crystalluria and urinary tract abnormalities associated with indinavir. | Annals of internal medicine 19970715 |
| Protease inhibitors and urolithiasis. | The Journal of urology 19970701 |
| Indinavir-induced nephropathy. | Tennessee medicine : journal of the Tennessee Medical Association 19970701 |
| [Crystalluria and nephrolithiasis during therapy with the protease inhibitor indinavir]. | Deutsche medizinische Wochenschrift (1946) 19970613 |
| Urinary stones in HIV-1-positive patients treated with indinavir. | Lancet (London, England) 19970503 |
| In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. | The Journal of infectious diseases 19970501 |
| [Kidney colic under Indinavir [correction of indiavir] therapy in HIV infection]. | Praxis 19970430 |
| Indinavir nephrolithiasis in warm climates. | Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 19970301 |
| Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. | Drug metabolism and disposition: the biological fate of chemicals 19970201 |
| Indinavir nephropathy. | The New England journal of medicine 19970109 |
| Indinavir urinary stones as origin of upper urinary tract obstruction. | Urologia internationalis 19970101 |
| [A new cause of nephritic colic: indinavir. Apropos of a case]. | La Revue de medecine interne 19970101 |
| [Urinary calculi and indinavir sulfate in patients with HIV infection. Apropos of 4 cases]. | Journal d'urologie 19970101 |
| Medical alert: hemolytic anemia in Crixivan cohort. | Critical Path AIDS project 19970101 |
| Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. | The Journal of biological chemistry 19961213 |
| Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. | Journal of virology 19961201 |
| Protease inhibitors shine in triple combinations. | AIDS alert 19960301 |
| Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. | Proceedings of the National Academy of Sciences of the United States of America 19960220 |
| In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. | Antiviral research 19960101 |
| Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. | Biochemistry 19950725 |
| In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. | Nature 19950406 |
| L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. | Journal of medicinal chemistry 19941014 |
| L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. | Proceedings of the National Academy of Sciences of the United States of America 19940426 |